Memorial Sloan Kettering Cancer Center-ko ikertzaileekin lankidetzan egindako argitalpenak (11)

2022

  1. The Oncogenic PI3K-Induced Transcriptomic Landscape Reveals Key Functions in Splicing and Gene Expression Regulation

    Cancer Research, Vol. 82, Núm. 12, pp. 2269-2280

2021

  1. TRK XDFG mutations trigger a sensitivity switch from type i to ii kinase inhibitors

    Cancer Discovery, Vol. 11, Núm. 1, pp. 126-141

2020

  1. FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer

    Cancer Cell, Vol. 38, Núm. 4, pp. 534-550.e9

2019

  1. PI3K Inhibition Activates SGK1 via a Feedback Loop to Promote Chromatin-Based Regulation of ER-Dependent Gene Expression

    Cell Reports, Vol. 27, Núm. 1, pp. 294-306.e5

2018

  1. Truncated SALL1 Impedes Primary Cilia Function in Townes-Brocks Syndrome

    American Journal of Human Genetics, Vol. 102, Núm. 2, pp. 249-265

2017

  1. Inhibition of Polo-like kinase 1 during the DNA damage response is mediated through loss of Aurora A recruitment by Bora

    Oncogene, Vol. 36, Núm. 13, pp. 1840-1848

  2. MTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer

    Nature, Vol. 547, Núm. 7661, pp. 109-113

2016

  1. Stratification and therapeutic potential of PML in metastatic breast cancer

    Nature Communications, Vol. 7

  2. The metabolic co-regulator PGC1α suppresses prostate cancer metastasis

    Nature Cell Biology, Vol. 18, Núm. 6, pp. 645-656

2015

  1. Methodological aspects of the molecular and histological study of prostate cancer: Focus on PTEN

    Methods, Vol. 77, pp. 25-30

1993

  1. Oleic acid blocks epidermal growth factor-activated early intracellular signals without altering the ensuing mitogenic response

    Experimental Cell Research, Vol. 205, Núm. 2, pp. 365-373